Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Andersen, MH; Fensterle, J; Ugurel, S; Reker, S; Houben, R; Guldberg, P; Berger, TG; Schadendorf, D; Trefzer, U; Brocker, EB; Straten, PT; Rapp, UR; Becker, JC.
Immunogenicity of constitutively active (V599E)BRaf
CANCER RES. 2004; 64(15): 5456-5460.
Doi: 10.1158/0008-5472.CAN-04-0937
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Becker Jürgen Christian
- Co-Autor*innen der Med Uni Graz
-
Ugurel-Becker Selma
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Activating BRAF somatic missense mutations within the kinase domain are present in 60-66% of melanomas. The vast majority of these represent a single substitution of glutamate for valine (V599E). Here, we demonstrate spontaneous HLA-B*2705-restricted cytotoxic T-cell responses against an epitope derived from (V599E)BRaf. These T-cell responses were mutation specific as the corresponding epitope derived from wild-type BRaf was not recognized. The loss of the (V599E)BRAF genotype during progression from primary to metastatic melanoma in patients with (V599E)BRaf specific T-cell responses suggests an active immune selection of nonmutated melanoma clones by the tumor-bearing host.
- Find related publications in this database (using NLM MeSH Indexing)
-
Disease Progression -
-
Epitopes - genetics Epitopes - immunology Epitopes - metabolism
-
Genotype -
-
HLA-B Antigens - immunology HLA-B Antigens - metabolism
-
HLA-B27 Antigen -
-
Humans -
-
Melanoma - genetics Melanoma - immunology Melanoma - secondary
-
Mutation, Missense -
-
Peptide Fragments - immunology Peptide Fragments - metabolism
-
Proto-Oncogene Proteins B-raf -
-
Proto-Oncogene Proteins c-raf - genetics Proto-Oncogene Proteins c-raf - immunology
-
Skin Neoplasms - genetics Skin Neoplasms - immunology Skin Neoplasms - metabolism
-
T-Lymphocytes, Cytotoxic - immunology T-Lymphocytes, Cytotoxic - metabolism